U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911489) titled 'Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients' on March 23.
Brief Summary: Stage 1 (Safety study for 68Ga-NRT6020 Injection):
The goal of this clinical trial stage is to evaluate the safety of 68Ga-NRT6020 Injection in participants with advanced solid tumors. The study will also assess the biodistribution, radiation dosimetry, imaging profile, and pharmacokinetics of the drug. Additionally, researchers aim to investigate how consistent the PET/CT imaging results of 68Ga-NRT6020 are with 18F-FDG PET/CT imaging and FAP immunohistochemistry (IHC) results.
Stage 2 (Safety and tolerability study for 1...